Meihua International Medical Technologies Co. Ltd. (MHUAF) Fair Value & Analysis
Healthcare · US · Market cap $7.1M · ISIN KYG5966G1165
What is Meihua International Medical Technologies Co. Ltd. really worth?
Meihua International Medical Technologies Co. Ltd.
MHUAF · US
Below-average quality, currently priced close to our fair value of $6.89.
Strengths
Risks
Fair value as of: Aug 20, 2026
From 21 valuation models · updated 12 days ago
Share price +4.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range ($4.83 to $8.96) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
54‑month range $2.05 – $3,900 · fair‑value band $4.83 – $8.96 · the $7.13 price screens above the $6.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Meihua International Medical Technologies Co. Ltd. (MHUAF) currently trades at $7.13, while our model-based Fair Value estimate is $6.89, implying the stock looks roughly 3.4% fairly valued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bull case: the Earnings-Based group reads highest at a median of $65.88 per share, and 21 of the 21 models we run sit above the $7.13 price. Bear case: the Growth DCF group reads lowest at $23.65, and 0 of the 21 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Meihua International Medical Technologies Co. Ltd. generated revenue of $61.8M at a net margin of 11.0%. Revenue declined 53.8% year over year. It earns a return on equity of 3.9%. The balance sheet holds a net cash position of $6.2M. Fundamentals as of Aug 20, 2026
Our scenario range runs from $4.83 (bear case) to $8.96 (bull case); at $7.13, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −47% fair-value upside, at −3%, MHUAF screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $12.06 per share, which is 174.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 21 models by family
Widest divergence: Asset-Based ($147.95) versus Growth DCF ($23.65). Highest evidence: FCF DCF (80).
Notify me when MHUAF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Meihua International Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of medical devices in the People's Republic of China, Europe, North America, South America, Asia, Africa, and Oceania.
Full company description
Meihua International Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of medical devices in the People's Republic of China, Europe, North America, South America, Asia, Africa, and Oceania. The company offers Class I disposable medical devices, including disposable medical X-ray films, medical dry films, dry laser imagers, gauze bandages, examination gloves, pharmaceutical packaging materials and containers, low-density polyethylene bottles for eye drops, and high-density polyethylene bottles for tablets; Class II products, such as disposable full anesthesia kits, medical brush, woman's examination kits, urethral catheterization kits, disposable bracelet, tube cleaning brush, gynecological examination and sterile surgical dressing kits, medical hand scrub, cervical sampling swab, catheter, hand washing brush, cervical liquid based cell sampler, surgical hats, suction connecting tube, nasal oxygen tube, endotracheal intubation, medical masks, anal bags, and suction connecting tube, etc.; and Class III disposable medical devices, such as disposable infusion pumps, anesthesia puncture kits, electronic pumps, etc. It also offers disposable plastic baby bottles, NB/PSN rubber covers and 8.2mL folded spoons for tools and containers, etc.; Class II 6866 medical polymer materials and products, including transfusion equipment and pipelines, endotracheal intubation for respiratory anesthesia or ventilation; medical devices, such as medical x-ray films and multi-functional self-extracting X-ray film machines; and provides SaaS development service to develop customized SaaS system covering the entire project lifecycle, including demand analysis, design, research and development, testing, launch, and maintenance support. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. The company was founded in 1991 and is headquartered in Yangzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Meihua International Medical Technologies Co. Ltd. reported revenue of $61.8M in FY2025 versus $104M in FY2021, a compound −12.2%/yr. Reported net income was $6.8M in FY2025, compounding −24.6%/yr from FY2021.
Watch MHUAF: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 205 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | −59% |
| EssilorLuxottica Société anonyme EL | €160.35 | €94.93 | −41% |
| Medline Inc MDLN | $34.58 | $30.15 | −13% |
| Becton, Dickinson and Company BDX | $190.21 | $100.46 | −47% |
| Alcon Inc ALC | $72.23 | $39.78 | −45% |
| ResMed Inc RMD | A$32.39 | A$26.05 | −20% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | −58% |
| Sartorius Stedim Biotech S.A DIM | €197.70 | €48.88 | −75% |
| Straumann Holding STMN | CHF 92.18 | CHF 47.31 | −49% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | −75% |
Compare Meihua International Medical Technologies Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Meihua International Medical Technologies Co. Ltd. (MHUAF) overvalued or undervalued?
What is the fair value of MHUAF?
What is the quality score of MHUAF?
What is the revenue of Meihua International Medical Technologies Co. Ltd. (MHUAF)?
What is the net profit margin of MHUAF?
Watch Meihua International Medical Technologies Co. Ltd. in the live analysis
One click puts Meihua International Medical Technologies Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.